Dr Stuart Cook grew up in Kenya, went to high school at St Edward’s, Oxford and studied medicine at St Bartholomew’s Medical School, London. He did a PhD at the National Heart and Lung Institute UK and a Postdoctoral Fellowship at Harvard. Stuart trained in clinical cardiology and specialized in cardiac MRI in London. He is a Group Head at the MRC London Institute of Medical Sciences and Professor at Imperial College and Duke-National University of Singapore (Duke-NUS). Furthermore, Stuart is a cardiologist at the National Heart Centre Singapore where he is the Director of the clinical cardiac MRI service. He is also the Director of the National Heart Research Institute Singapore and Program Director of the CVMD program at Duke-NUS. Stuart leads a cross-disciplinary research team that is centered on genomic discovery sciences in humans.
Dr Sebastian Schäfer is a Senior Research Fellow at the National Heart Centre Singapore and Assistant Professor at Duke-NUS Medical School, where he developed the technology licensed to Enleofen Bio together with Dr Stuart Cook. He studied Bioengineering (Dipl.-Ing.) at the University of Erlangen-Nuremberg, Germany and Biotechnology (M.Sc.) at Dongseo University in Busan, South Korea. Before Sebastian obtained his doctoral degree in genetics at the Max Delbrück Center in Berlin, he worked at Harvard-MIT Health Sciences and Technology. His work has been published in high-ranking scientific journals including Nature Nanotechnology, Science, Nature Medicine and Nature Genetics.
Andrew Khoo is the CEO and Co-founder of Tessa Therapeutics, an international biotechnology company specialized in virus-associated cancer immunotherapy. Under Andrew’s leadership, Tessa has grown to become a 120+ employee company, with operations across 5 countries, and is also currently running the world’s largest Phase 3 adoptive T cell therapy trial for any cancer indication. An active investor in healthcare and technology focused start-ups, he is also a Director of other leading biotechnology companies such as Euchloe Bio, that specializes in the development and commercialization of antibodies to treat cancer, and Vyriad, a Mayo Clinic biotech developing oncolytic virotherapy. Prior to his involvement with Tessa, Andrew worked in various roles at global investment banks including JP Morgan and Citigroup. He began his career at the Singapore Economic Development Board after graduating from Stanford University on a full government scholarship.
Jeffrey Lu is an experienced entrepreneur, corporate executive, and investor in technology and life sciences. He is currently co-founder and CEO of Engine Biosciences, which builds upon novel experimental biology and data science developed previously at MIT, Harvard, Mayo Clinic, and UCSD to decipher biological complexity for breakthrough drug discovery and other applications. As a private investor, he has led deals in a large number of early and growth stage companies, serving as board director and/or advisor and resulting in notable IPOs and trade sales. He has previously built two companies towards highly profitable exits at a total combined valuation of US$450M. Earlier in his career, Jeff was a consultant at Bain & Company, where his clients included private equity and large corporates in healthcare, TMT, financial services, and travel, and prior to that he worked at a technology-focused hedge fund. He received his bachelor’s degree summa cum laude from the University of Pennsylvania.
Dr Guy Heathers has over 30 years of international experience in growing and developing technologies for healthcare companies, specializing in the Life Sciences industry. Guy is Vice President of Business Development at Tessa Therapeutics and Director of Technology Development at the National Cancer Centre of Singapore. Previously, Guy also held senior leadership positions at Cancer Therapeutics, Amaranth Medical, Gateway Capital, Biotech Research Ventures, and Cancer Research Ventures. Guy obtained his Ph.D. in cardiovascular research from the University of Bath, UK, completed his post-doctoral research at Washington University Medical School, St. Louis, USA and his M.B.A. at Fairleigh Dickenson University, New Jersey, USA.
Dr Timothy Lu is a leader in the field of synthetic biology and has been a co-founder of several successful biotechnology companies. He holds positions as an Associate Professor at MIT, the leader of MIT’s RLE Synthetic Biology Group, and an Associate Member of the Broad Institute of MIT and Harvard. Tim is a pioneer in applying synthetic biology to tackle important medical and industrial problems. Among the numerous awards he’s received are the NIH New Innovator Award, the U.S. Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award. Passionate about generating real-world impact from innovative technologies, Tim has co-founded several notable biotechnology companies, working with leading VCs and investors, including Gates Foundation, J&J, Orbimed, Third Rock Ventures, Atlas Venture, Flybridge, and NEA. These include Synlogic (engineered probiotic platform company with programs entering clinic), Sample6 (commercial stage food safety diagnostics company), Tango Therapeutics, and others. Tim received his M.D. from Harvard Medical School, his Ph.D. from the Harvard-MIT Sciences and Technology Program, and his S.B. and S.M. from MIT.
Susanne Weber has a master’s degree in business administration from University of Regensburg, Germany and studied international business and trade at American University in Washington DC, USA. She worked as a project manager in the creative industry in Berlin before moving to Singapore, where she joined the Singaporean-German Chamber of Industry and Commerce as senior consultant to promote business relations between companies from Germany and Singapore.
Scientific Advisory Board
Dr Norbert Hubner studied Medicine at the Heidelberg University and Charité Medical School Berlin. He did his doctoral thesis work with Prof Klaus Lindpaintner in the Department of Cardiology, Children’s Hospital, Harvard Medical School and a Postdoctoral Fellowship at the Max-Delbrück-Center for Molecular Medicine (MDC) with Prof Detlev Ganten as mentor. Norbert studies cardiovascular and inflammatory diseases across the physiological scale in cells and tissues from rodents and humans. His laboratory uses state-of-the-art and emerging large-scale technologies and advanced computation in an expanded multi-disciplinary approach to identify genes, gene networks, and genomic mechanisms underlying common cardiovascular and inflammatory diseases. Norbert is a Professor of Cardiovascular and Metabolic Sciences at Charité Medical School Berlin and Group Head at the Max-Delbrueck-Center for Molecular Medicine (MDC) in Berlin. He led several multi-institutional and international grants and is the Coordinator of the Cardiovascular and Metabolic Disease Program at the MDC. Moreover, he is the Speaker of the CVMD Program within the Helmholtz Association in Germany.
Dr Todd Juan has over 25 years of biopharmaceutical industry experience, specialized in research, development, and commercialization of biologics for human disease treatment. He has co-founded and built a biologics manufacturing and development company in Asia, JHL Biotech, and built R&D pipeline as well as CMO manufacturing projects. JHL Biotech has grown into a world-class CMO manufacturing house and biosimilar development company in greater China, and was successfully brought to the public market in Taiwan. Prior to JHL, Todd worked at Amgen Inc for 18 years in Research, Preclinical Development, Translation Medicine, and Commercialization. During his tenure, he has built and managed Amgen pipeline biologics products in the areas of Inflammation, Hematology, Oncology, Metabolism, and Neuroscience. He invented the first commercial product driven predictive markers, kRAS mutation, and resulted in approval in EU for panitumumab. He also led the technology development team for biologics and drove development of antibody development programs for Amgen’s successful product development, including panitumumab, denosumab, brodalumab, evolocumab, among others. His visionary biomarker work also helped development programs such as motesanib and laid the foundation of precision medicine for the modern day biomedical R&D. He co-authored and helped file 21 patents in US and worldwide during his Amgen tenure. Currently, he works at InnoBiopharm Limited, a new startup in Asia, and continues to push breakthrough biologics in medicine to help patients in Asia and worldwide. Prior to Amgen, Todd obtained his PhD degree in the area of Human and Molecular Genetics from Baylor College of Medicine at Houston, Texas.
Dr Tracy Putoczki is a leader in animal models of inflammatory disease, with a particular research focus on how cytokines modulate disease pathology. She revealed important roles for Interleukin 11 (IL11) in human disease and is considered a world expert in IL11 biology. Tracy completed her undergraduate research training at the University of Toronto Canada, her PhD training at the University of Canterbury New Zealand, and postdoctoral training at the Ludwig Institute for Cancer Research, Australia and the Walter and Eliza Hall Institute of Medical Research, Australia.
Dr Shelia Violette is a leader in the field of inflammation and fibrosis with depth of industry experience in translational research and drug development. She was previously Vice President of Tissue Injury and Fibrosis Research at Biogen where she spearheaded a team of scientists conducting discovery research and advanced programs into clinical development. From 2008 to 2012, Shelia was Vice President of Research at Stromedix and led all research activities supporting the development of the anti-avb6 antibody, STX-100. She has provided strategic and operational leadership to multi-disciplinary teams of scientists and authored more than 80 manuscripts and patents. Shelia has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen. She is currently an Entrepreneur in Residence at Atlas Venture, Cambridge, MA. Shelia received her Ph.D. in Pharmacology from Yale University and carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.
Dr Tina Wong is Associate Professor and Head of the Glaucoma Service at the Singapore National Eye Centre, and Head of Ocular Therapeutics and Drug Delivery Research Group at the Singapore Eye Research Institute, Duke-NUS Graduate Medical School. She also holds an adjunct faculty position at the School of Materials Science and Engineering at Nanyang Technological University, and is co-Director of the Ocular Therapeutics and Engineering Centre. Furthermore, she is the Executive Director for the National Health and Innovation Centre, which manages funding for research projects with commercial healthcare outcomes, and serves on scientific review panels for the National Medical Research Council and the Ministry of Health of Singapore. Her research interests are in ocular wound repair and regeneration, with the goal of identifying new fibrotic therapeutic targets and the application sustained delivery systems to improve on current medical and surgical treatments in ophthalmology. Tina trained at Moorfields Eye Hospital, UK, and is a Wellcome Trust Vision Research Fellow, completing a PhD at the Institute of Ophthalmology.